11:02:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Iconovo utvecklar inhalatorer för medicinskt bruk. Bolagets produkter används vid behandling utav astma och kol, där inhalatorerna består av pulverbaserat läkemedel. Produkterna licensieras ut och säljs under varierade varumärken. Utöver produktutveckling återfinns kompetens inom läkemedelsformulering. Bolaget grundades under 2013 och har sitt huvudkontor i Lund.


2020-10-27 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ICO 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2019
2020-03-11 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-16 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning ICO 0.00 SEK
2019-05-15 Årsstämma 2018
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-16 Årsstämma 2017
2018-04-19 Kvartalsrapport 2018-Q1
2019-11-19 15:09:09

The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several granted ICOres patents in Sweden and in Europe, but this is the first in Japan. ICOres is the dry powder inhaler used in Iconovo’s two major customer projects including generic SymbicortÒ. 

”A granted patent is the key to this huge and important market. This will be an advantage to our customers when launching ICOres products in Japan”, says Dr Orest Lastow, CEO.

For further information please contact:
Orest Lastow, VD, orest.lastow@iconovo.se, telephone: 076-5422220.

About ICOres
ICOres is a novel reservoir-based dry powder inhaler developed by Iconovo. It can be designed in many different shapes and colors and customized to meet a customer’s unique requirements. ICOres has two separate reservoirs and is particularly suitable for combination products. ICOres has several unique compliance enhancing features as an accurate dose counter showing each remaining dose, a visual feedback feature showing when the dose is ready for inhalation and when a successful inhalation has been completed.

About Iconovo
Iconovo was founded 2013 by people with a long experience in the development of inhalation products. The company develops inhalers and accompanying powder formulation mainly to treat asthma and COPD. Iconovo also has the competence to develop products for new types of inhaled pharmaceuticals like vaccines.
By collaborating with Iconovo, innovative and generic pharmaceutical companies can get access to a complete inhalation product, avoiding the complicated and costly early stages in the development process. Iconovo license out their patented products to their customers thereby offering a faster way to the inhalation market with less risk and costs. 

More information about Iconovo can be found at www.iconovo.se.
The company is based in Lund and the shares of Iconovo (ticker ICO) are listed on Nasdaq First North Growth Market, Stockholm since April 6th, 2018. Certified Adviser is Erik Penser Bank AB, telephone +46 8 463 80 00, email: certifiedadviser@penser.se.